PT101388B - Solucoes de infusao de acido tioctico sob a forma dos seus sais soluveis em agua e ampola para aplicacao parenteral - Google Patents
Solucoes de infusao de acido tioctico sob a forma dos seus sais soluveis em agua e ampola para aplicacao parenteral Download PDFInfo
- Publication number
- PT101388B PT101388B PT101388A PT10138893A PT101388B PT 101388 B PT101388 B PT 101388B PT 101388 A PT101388 A PT 101388A PT 10138893 A PT10138893 A PT 10138893A PT 101388 B PT101388 B PT 101388B
- Authority
- PT
- Portugal
- Prior art keywords
- thioctic acid
- solutions
- water
- solution
- parenteral application
- Prior art date
Links
- 239000003978 infusion fluid Substances 0.000 title claims description 7
- 239000000243 solution Substances 0.000 title description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 6
- 239000002253 acid Substances 0.000 title 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 33
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 32
- 235000019136 lipoic acid Nutrition 0.000 claims description 32
- 229960002663 thioctic acid Drugs 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003708 ampul Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000007872 degassing Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 3
- XZUAPPXGIFNDRA-UHFFFAOYSA-N ethane-1,2-diamine;hydrate Chemical compound O.NCCN XZUAPPXGIFNDRA-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010036106 Polyneuropathy alcoholic Diseases 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000020701 alcoholic polyneuropathy Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- ZYTYOUNYLKOKAR-UHFFFAOYSA-N morpholine;pyrrolidine Chemical compound C1CCNC1.C1COCCN1 ZYTYOUNYLKOKAR-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE9213914U DE9213914U1 (de) | 1992-10-15 | 1992-10-15 | Ampulle und Infusionslösung von Thioctsäure in Form der wasserlöslichen Salze der Thioctsäure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT101388A PT101388A (pt) | 1994-09-30 |
| PT101388B true PT101388B (pt) | 1999-09-30 |
Family
ID=6884846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT101388A PT101388B (pt) | 1992-10-15 | 1993-10-14 | Solucoes de infusao de acido tioctico sob a forma dos seus sais soluveis em agua e ampola para aplicacao parenteral |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE1007420A3 (no) |
| DE (1) | DE9213914U1 (no) |
| ES (1) | ES2063713B1 (no) |
| FR (1) | FR2696933B3 (no) |
| IT (1) | IT1260996B (no) |
| NL (1) | NL9301781A (no) |
| PT (1) | PT101388B (no) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4433764A1 (de) * | 1994-09-22 | 1996-03-28 | Asta Medica Ag | Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit |
| DE29506604U1 (de) * | 1995-04-25 | 1995-06-14 | Asta Medica Ag, 01277 Dresden | Fertiginfusionsset |
| ITMI20111975A1 (it) * | 2011-10-28 | 2013-04-29 | Labomar S R L | Composizioni comprendenti un sale di un acido organico. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1095991B (de) * | 1959-05-09 | 1960-12-29 | Chemiewerk Homburg Zweignieder | Verfahren zur Herstellung einer stabilen und injizierbaren 1,2-Dithia-cyclopentan-3-valeriansaeure enthaltenden Loesung |
| JPS3814940B1 (no) * | 1961-03-04 | 1963-08-15 | ||
| JPS3922715B1 (no) * | 1962-03-29 | 1964-10-13 | ||
| DE1668887B2 (de) * | 1968-03-15 | 1976-06-16 | Ca-salz der 1,2 -dithia-cyclopentan - 3- valerian saeure gleich (thioctsaeure) | |
| JPS4526516B1 (no) * | 1968-07-08 | 1970-09-01 | ||
| JPS6066955A (ja) * | 1983-09-19 | 1985-04-17 | Kiyaraban:Kk | ドレッシングの製造方法 |
| IT1213141B (it) * | 1984-02-17 | 1989-12-14 | Dobrivoje Tomic | Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche. |
| DE3512911A1 (de) * | 1985-04-11 | 1986-10-16 | Degussa Ag, 6000 Frankfurt | Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure) |
| ATE70974T1 (de) * | 1987-12-04 | 1992-01-15 | Asta Pharma Ag | Injizierbare loesung des thioctsaeuresalzes mit trometamol und/oder basischen aminosaeuren. |
| DK0427247T3 (da) * | 1989-11-09 | 1998-09-28 | Asta Medica Ag | Lægemiddel indeholdende R-alpha- lipoinsyre eller S-alphalipoinsyre som aktiv bestanddel |
| IE67874B1 (en) * | 1989-11-09 | 1996-05-01 | Asta Medica Ag | Medicaments containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses |
-
1992
- 1992-10-15 DE DE9213914U patent/DE9213914U1/de not_active Expired - Lifetime
-
1993
- 1993-09-03 BE BE9300910A patent/BE1007420A3/fr not_active IP Right Cessation
- 1993-09-16 FR FR9311052A patent/FR2696933B3/fr not_active Expired - Lifetime
- 1993-10-14 PT PT101388A patent/PT101388B/pt not_active IP Right Cessation
- 1993-10-14 NL NL9301781A patent/NL9301781A/nl active Search and Examination
- 1993-10-14 ES ES09302159A patent/ES2063713B1/es not_active Expired - Fee Related
- 1993-10-15 IT ITTO930761A patent/IT1260996B/it active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2063713A1 (es) | 1995-01-01 |
| IT1260996B (it) | 1996-04-29 |
| FR2696933A3 (fr) | 1994-04-22 |
| NL9301781A (nl) | 1994-05-02 |
| ITTO930761A0 (it) | 1993-10-15 |
| FR2696933B3 (fr) | 1994-09-23 |
| PT101388A (pt) | 1994-09-30 |
| DE9213914U1 (de) | 1992-12-03 |
| BE1007420A3 (fr) | 1995-06-13 |
| ES2063713B1 (es) | 1995-07-16 |
| ITTO930761A1 (it) | 1995-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100258423B1 (ko) | 오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트 | |
| KR101119334B1 (ko) | 투석 요법용 중탄산염-기재 용액 | |
| PT1455782E (pt) | Soluções estáveis de meloxicam de concentração elevada para injecção sem agulha. | |
| PT1054665E (pt) | Composicao farmaceutica compreendendo uma combinacao de metformina e fibrato e seu uso no tratamento da hiperglicemia | |
| JP2008539269A (ja) | 疼痛を治療するための方法および組成物 | |
| UA72268C2 (uk) | Водна композиція моксифлоксацину, що містить хлорид натрію | |
| PT97785B (pt) | Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina | |
| PT85293B (pt) | Processo para a preparacao de solucoes de oxazafosforinas com estabilidade melhorada | |
| PT1609481E (pt) | Composições farmacêuticas injectáveis compreendendo diclofenaco de sódio de beta-ciclodextrina e um polissorbato | |
| US20220370400A1 (en) | Pharmaceutical compositions of furosemide and uses thereof | |
| JP2003300905A (ja) | 非ステロイド抗炎症剤を含む注射可能な薬学組成物及び調製法 | |
| ES2272720T3 (es) | Formulacion de esmolol. | |
| PT101388B (pt) | Solucoes de infusao de acido tioctico sob a forma dos seus sais soluveis em agua e ampola para aplicacao parenteral | |
| JPS61502821A (ja) | 薬物キットまたは薬物組成物 | |
| EA033988B1 (ru) | Инъецируемые фармацевтические композиции лефамулина | |
| JP3720262B2 (ja) | 安定化したカルベジロール注射溶液 | |
| Donnelly et al. | Cardioplegia solutions | |
| US4289783A (en) | Etomidate-containing compositions | |
| BRPI0714012A2 (pt) | formulaÇço farmacÊutica aquosa de Ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-benzil)àxi]-fenetil}am ino)metil]benzàico | |
| BR112020005703A2 (pt) | formulação parentérica compreendendo siponimod | |
| BR112019011914A2 (pt) | formulação líquida parenteral, composição injetável, e, método para preparar uma formulação líquida parenteral. | |
| PT85612B (pt) | Processo para a preparacao de composicoes farmaceuticas liofilizadas contendo acidos fenilquinolinocarboxilicos | |
| JP4463206B2 (ja) | グリチルリチン高濃度製剤 | |
| HU196307B (en) | Process for producing vermicides comprising levamisole-nitroxinil salt | |
| CN1151782C (zh) | 一种具有哺乳动物麻醉的诱导和保持以及镇静用途的药用注射液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 19940519 |
|
| FG3A | Patent granted, date of granting |
Effective date: 19990628 |
|
| PC3A | Transfer or assignment |
Free format text: ASTA MEDICA HEALTH PRODUCTS GMBH & CO. KG DE Effective date: 20020909 |
|
| PD3A | Change of proprietorship |
Free format text: ASTA MEDICA GMBH DE Effective date: 20020909 Free format text: VIATRIS GMBH & CO. KG DE Effective date: 20020909 |
|
| TE3A | Change of address (patent) |
Free format text: VIATRIS GMBH & CO. KG DE Effective date: 20050506 |
|
| PD4A | Change of proprietorship |
Owner name: MEDA PHARMA GMBH & CO. KG, DE Effective date: 20070604 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20140630 |